Skip to main content
NCBI home page
Heart logoLink to Heart
. 2001 Dec;86(6):661–665. doi: 10.1136/heart.86.6.661

Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue

C Vizza 1, S Sciomer 1, S Morelli 1, C Lavalle 1, M Di 1, D Padovani 1, R Badagliacca 1, A Vestri 1, R Naeije 1, F Fedele 1
PMCID: PMC1730044  PMID: 11711462

Abstract

OBJECTIVE—To evaluate the effects of one year's treatment with beraprost, an orally active prostacyclin analogue, in patients with severe pulmonary hypertension.
PATIENTS—13 patients with severe pulmonary hypertension. This was primary in nine, thromboembolic in three, and caused by Eisenmenger syndrome in one.
METHODS—All patients underwent right heart catheterisation. Mean (SD) right atrial pressure was 5 (3) mm Hg, mean pulmonary artery pressure was 48 (12) mm Hg, cardiac index was 2.6 (0.8) l/min/m2, and mixed venous oxygen saturation was 68 (7)%. Beraprost was started at the dose of 20 µg three to four times a day (1 µg/kg/day), increasing after one month to 40 µg three to four times a day (2 µg/kg/day), with further increases of 20 µg three to four times a day in case of clinical deterioration.
MAIN OUTCOME MEASURES—New York Heart Association (NYHA) functional class, exercise capacity measured by distance walked in six minutes, and systolic pulmonary pressure (by echocardiography) were evaluated at baseline, after one month's treatment, and then every three months for a year.
RESULTS—After the first month of treatment, NYHA class decreased from 3.4 (0.7) to 2.9 (0.7) (p < 0.05), the six minute walking distance increased from 213 (64) to 276 (101) m (p < 0.05), and systolic pulmonary artery pressure decreased from 93 (15) to 85 (18) mm Hg (NS). One patient died after 40 days from refractory right heart failure, and another was lost for follow up at six months. The 11 remaining patients had persistent improvements in functional class and exercise capacity and a significant decrease in systolic pulmonary artery pressure in the period from 1-12 months. Side effects were minor.
CONCLUSIONS—Oral administration of beraprost may result in long lasting clinical and haemodynamic improvements in patients with severe pulmonary hypertension.


Keywords: pulmonary arterial hypertension; prostacyclin; beraprost

Full Text

The Full Text of this article is available as a PDF (106.4 KB).

Figure 1  .

Figure 1  

Open in a new tab

Individual values (thin lines) of distances walked in six minutes (SMWT) in patients with severe pulmonary hypertension at baseline and after 1, 3, 6, 9, and 12 months of treatment with oral beraprost. Thick lines with data points and vertical bars represent the mean responses with SEM. *p < 0.05 v baseline.

Figure 2  .

Figure 2  

Open in a new tab

Systolic pulmonary artery pressures (Ppas) estimated by Doppler echocardiography in patients with severe pulmonary hypertension at baseline and after 1, 3, 6, 9, and 12 months of treatment with oral beraprost. Thick lines with data points and vertical bars represent the mean responses with SEM. *p < 0.05 v baseline.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Badesch D. B., Tapson V. F., McGoon M. D., Brundage B. H., Rubin L. J., Wigley F. M., Rich S., Barst R. J., Barrett P. S., Kral K. M. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000 Mar 21;132(6):425–434. doi: 10.7326/0003-4819-132-6-200003210-00002. [DOI] [PubMed] [Google Scholar]
  2. Barst R. J., Rubin L. J., Long W. A., McGoon M. D., Rich S., Badesch D. B., Groves B. M., Tapson V. F., Bourge R. C., Brundage B. H. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 1;334(5):296–301. doi: 10.1056/NEJM199602013340504. [DOI] [PubMed] [Google Scholar]
  3. Barst R. J., Rubin L. J., McGoon M. D., Caldwell E. J., Long W. A., Levy P. S. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994 Sep 15;121(6):409–415. doi: 10.7326/0003-4819-121-6-199409150-00003. [DOI] [PubMed] [Google Scholar]
  4. Guyatt G. H., Thompson P. J., Berman L. B., Sullivan M. J., Townsend M., Jones N. L., Pugsley S. O. How should we measure function in patients with chronic heart and lung disease? J Chronic Dis. 1985;38(6):517–524. doi: 10.1016/0021-9681(85)90035-9. [DOI] [PubMed] [Google Scholar]
  5. Higenbottam T. W., Spiegelhalter D., Scott J. P., Fuster V., Dinh-Xuan A. T., Caine N., Wallwork J. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J. 1993 Oct;70(4):366–370. doi: 10.1136/hrt.70.4.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hoeper M. M., Schwarze M., Ehlerding S., Adler-Schuermeyer A., Spiekerkoetter E., Niedermeyer J., Hamm M., Fabel H. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000 Jun 22;342(25):1866–1870. doi: 10.1056/NEJM200006223422503. [DOI] [PubMed] [Google Scholar]
  7. Humbert M., Sanchez O., Fartoukh M., Jagot J. L., Le Gall C., Sitbon O., Parent F., Simonneau G. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J. 1999 Jun;13(6):1351–1356. doi: 10.1183/09031936.99.13613579. [DOI] [PubMed] [Google Scholar]
  8. Ichida F., Uese K., Tsubata S., Hashimoto I., Hamamichi Y., Fukahara K., Murakami A., Miyawaki T. Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension. Am J Cardiol. 1997 Sep 1;80(5):662–664. doi: 10.1016/s0002-9149(97)00447-5. [DOI] [PubMed] [Google Scholar]
  9. McLaughlin V. V., Genthner D. E., Panella M. M., Hess D. M., Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med. 1999 May 4;130(9):740–743. doi: 10.7326/0003-4819-130-9-199905040-00014. [DOI] [PubMed] [Google Scholar]
  10. McLaughlin V. V., Genthner D. E., Panella M. M., Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998 Jan 29;338(5):273–277. doi: 10.1056/NEJM199801293380501. [DOI] [PubMed] [Google Scholar]
  11. Moser K. M., Auger W. R., Fedullo P. F., Jamieson S. W. Chronic thromboembolic pulmonary hypertension: clinical picture and surgical treatment. Eur Respir J. 1992 Mar;5(3):334–342. [PubMed] [Google Scholar]
  12. Murata T., Murai T., Kanai T., Ogaki Y., Sanai K., Kanda H., Sato S., Kajikawa N., Umetsu T., Matsuura H. General pharmacology of beraprost sodium. 2nd communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects. Arzneimittelforschung. 1989 Aug;39(8):867–876. [PubMed] [Google Scholar]
  13. Nagaya N., Uematsu M., Okano Y., Satoh T., Kyotani S., Sakamaki F., Nakanishi N., Miyatake K., Kunieda T. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999 Oct;34(4):1188–1192. doi: 10.1016/s0735-1097(99)00312-5. [DOI] [PubMed] [Google Scholar]
  14. Okano Y., Yoshioka T., Shimouchi A., Satoh T., Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet. 1997 May 10;349(9062):1365–1365. doi: 10.1016/S0140-6736(97)24019-5. [DOI] [PubMed] [Google Scholar]
  15. Olschewski H., Ghofrani H. A., Schmehl T., Winkler J., Wilkens H., Höper M. M., Behr J., Kleber F. X., Seeger W. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med. 2000 Mar 21;132(6):435–443. doi: 10.7326/0003-4819-132-6-200003210-00003. [DOI] [PubMed] [Google Scholar]
  16. Rich S., Dantzker D. R., Ayres S. M., Bergofsky E. H., Brundage B. H., Detre K. M., Fishman A. P., Goldring R. M., Groves B. M., Koerner S. K. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987 Aug;107(2):216–223. doi: 10.7326/0003-4819-107-2-216. [DOI] [PubMed] [Google Scholar]
  17. Rosenzweig E. B., Kerstein D., Barst R. J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999 Apr 13;99(14):1858–1865. doi: 10.1161/01.cir.99.14.1858. [DOI] [PubMed] [Google Scholar]
  18. Rubin L. J., Mendoza J., Hood M., McGoon M., Barst R., Williams W. B., Diehl J. H., Crow J., Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990 Apr 1;112(7):485–491. doi: 10.7326/0003-4819-112-7-485. [DOI] [PubMed] [Google Scholar]
  19. Rubin L. J. Primary pulmonary hypertension. N Engl J Med. 1997 Jan 9;336(2):111–117. doi: 10.1056/NEJM199701093360207. [DOI] [PubMed] [Google Scholar]
  20. Saji T., Ozawa Y., Ishikita T., Matsuura H., Matsuo N. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol. 1996 Jul 15;78(2):244–247. doi: 10.1016/s0002-9149(96)90408-7. [DOI] [PubMed] [Google Scholar]
  21. Shapiro S. M., Oudiz R. J., Cao T., Romano M. A., Beckmann X. J., Georgiou D., Mandayam S., Ginzton L. E., Brundage B. H. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol. 1997 Aug;30(2):343–349. doi: 10.1016/s0735-1097(97)00187-3. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES